1st treatment for EGFR+ NSCLC with exon 19 deletions or exon 21 L858R mutations
RYBREVANT® + LAZCLUZE™ are targeted treatments that work together to fight cancer without needing chemotherapy.
RYBREVANT® is a targeted antibody* that works against EGFR mutations. LAZCLUZE™ is an EGFR-targeted TKI (tyrosine kinase inhibitor). RYBREVANT® + LAZCLUZE™ work against cancer in different ways:
RYBREVANT® helps stop the activity cancer cells use to grow and spread from outside the cancer cell.
RYBREVANT® also works with your immune system to help destroy the cancer.
LAZCLUZE™ helps stop the activity cancer cells use to grow and spread from inside the cancer cell.
*Antibodies are protective proteins that help detect harmful substances and diseases such as cancers. They are made naturally by your immune system and can also be man-made. Man-made antibodies used to treat cancer have a specific target on a cancer cell that they aim to find, attach to, and attack. RYBREVANT® is a man-made antibody.
Side effects
There are side effects that you may experience during treatment with RYBREVANT®.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.